Michitaka Imai

8PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersDiagnostic radiography
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

|Nov 11, 2025
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease.

Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka

|Jan 23, 2025
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada

|Jan 06, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka

|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka

Pageof 2

Frequent Collaborators

7 joint publications

Atsushi Hiraoka

7 joint publications

Takashi Kumada

7 joint publications

Kazuya Kariyama

7 joint publications

Toshifumi Tada